What is a stock summary page? Click here for an overview.
Business Description
Beta Bionics Inc
NAICS : 339112
SIC : 5047
ISIN : US08659B1026
Description
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 14.28 | |||||
Equity-to-Asset | -1.64 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.9 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.93 | |||||
Beneish M-Score | 7.93 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.95 | |||||
9-Day RSI | 47.96 | |||||
14-Day RSI | 42.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.29 | |||||
Quick Ratio | 5.66 | |||||
Cash Ratio | 4.9 | |||||
Days Inventory | 359.48 | |||||
Days Sales Outstanding | 142.31 | |||||
Days Payable | 95.46 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 57.19 | |||||
Operating Margin % | -63.78 | |||||
Net Margin % | -88.59 | |||||
FCF Margin % | -32.58 | |||||
ROA % | -15.23 | |||||
ROIC % | -48.31 | |||||
ROC (Joel Greenblatt) % | -59.19 | |||||
ROCE % | -8.41 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 23.19 | |||||
EV-to-EBIT | -41.55 | |||||
EV-to-EBITDA | -44.27 | |||||
EV-to-Revenue | 17.49 | |||||
EV-to-FCF | -53.68 | |||||
Earnings Yield (Greenblatt) % | -2.41 | |||||
FCF Yield % | -1.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beta Bionics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 20.44 | ||
EPS (TTM) ($) | -0.422 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | - | ||
14-Day RSI | 42.59 | ||
14-Day ATR ($) | 1.213882 | ||
20-Day SMA ($) | 10.957 | ||
12-1 Month Momentum % | - | ||
52-Week Range ($) | 8.89 - 24.5 | ||
Shares Outstanding (Mil) | 43.35 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Beta Bionics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Beta Bionics Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Beta Bionics Inc Frequently Asked Questions
What is Beta Bionics Inc(BBNX)'s stock price today?
The current price of BBNX is $11.06. The 52 week high of BBNX is $24.50 and 52 week low is $8.89.
When is next earnings date of Beta Bionics Inc(BBNX)?
The next earnings date of Beta Bionics Inc(BBNX) is 2025-05-06.
Does Beta Bionics Inc(BBNX) pay dividends? If so, how much?
Beta Bionics Inc(BBNX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |